Seizert Capital Partners LLC Has $6.07 Million Stake in Biogen Inc. (NASDAQ:BIIB)

Seizert Capital Partners LLC increased its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 260.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,671 shares of the biotechnology company’s stock after acquiring an additional 28,667 shares during the quarter. Seizert Capital Partners LLC’s holdings in Biogen were worth $6,066,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Ashton Thomas Securities LLC bought a new position in shares of Biogen in the third quarter valued at about $33,000. SRS Capital Advisors Inc. bought a new position in Biogen in the 4th quarter valued at about $33,000. Golden State Wealth Management LLC acquired a new stake in Biogen during the fourth quarter worth approximately $41,000. Venturi Wealth Management LLC boosted its holdings in shares of Biogen by 73.8% during the third quarter. Venturi Wealth Management LLC now owns 219 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 93 shares during the period. Finally, Itau Unibanco Holding S.A. increased its stake in shares of Biogen by 63.8% during the third quarter. Itau Unibanco Holding S.A. now owns 231 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 90 shares during the period. Institutional investors own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on BIIB. Bank Of America (Bofa) decreased their price objective on Biogen from $178.00 to $163.00 and set a “neutral” rating on the stock in a report on Tuesday, February 11th. The Goldman Sachs Group lowered their price target on shares of Biogen from $281.00 to $245.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. BMO Capital Markets cut their price objective on shares of Biogen from $156.00 to $139.00 and set a “market perform” rating for the company in a report on Thursday, February 13th. William Blair reaffirmed an “outperform” rating on shares of Biogen in a report on Monday, January 13th. Finally, Wells Fargo & Company cut their price target on Biogen from $165.00 to $140.00 and set an “equal weight” rating for the company in a research note on Thursday, February 13th. Seventeen investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $213.33.

Biogen Trading Up 0.7 %

Shares of NASDAQ BIIB opened at $142.65 on Wednesday. The stock has a market cap of $20.88 billion, a P/E ratio of 12.75, a price-to-earnings-growth ratio of 1.51 and a beta of -0.08. The firm has a 50 day moving average price of $144.15 and a two-hundred day moving average price of $167.42. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. Biogen Inc. has a 52-week low of $128.51 and a 52-week high of $238.00.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. As a group, equities analysts forecast that Biogen Inc. will post 15.83 EPS for the current year.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.